Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response

Bone Marrow Transplantation
L S LambP J Henslee-Downey

Abstract

Refractory acute lymphoblastic leukemia (ALL) is often incurable, and relapse rates following allogeneic bone marrow transplantation (BMT) remain high. We have reported that patients who develop increased numbers of gammadelta(+) T cells soon after BMT are significantly less likely to relapse. We now show in seven donor/recipient pairs that donor-derived Vdelta1(+)CD4(-)CD8(-)gammadelta(+) T cells are activated and proliferate in response to recipient primary ALL blasts. In addition, these cells have been shown to bind and lyse the recipient ALL blasts. Separately, gammadelta(+) T cells proliferate poorly or not at all in mixed lymphocyte culture against HLA-mismatched unrelated stimulator cells. These observations suggest that allogeneic gammadelta(+) T cells could be an effective immunotherapeutic strategy against refractory disease without the risk of graft-versus-host disease.

References

Aug 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M SykesD H Sachs
Jun 22, 1999·Lancet·J J MelenhorstJ H Falkenburg

❮ Previous
Next ❯

Citations

Dec 6, 2005·Cancer Immunology, Immunotherapy : CII·Paul F MeehLawrence S Lamb
Apr 27, 2013·Cancer Immunology, Immunotherapy : CII·Christel DevaudMyriam Capone
Aug 28, 2009·Immunologic Research·Lawrence S Lamb
Jan 9, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Drew C DenigerLaurence J N Cooper
Jul 27, 2001·British Journal of Haematology·M W LowdellH G Prentice
Mar 22, 2013·Clinical and Vaccine Immunology : CVI·Juan C Andreu-BallesterFerran Ballester
Feb 23, 2011·Future Virology·C David PauzaRobert R Redfield
Mar 5, 2011·Digestive Diseases and Sciences·Juan Carlos Andreu-BallesterCarlos Peñarroja-Otero
Jul 16, 2005·Leukemia & Lymphoma·Volker Kunzmann, Martin Wilhelm
Mar 1, 2012·Trends in Immunology·Dalil HannaniLaurence Zitvogel
Aug 26, 2015·Nature Reviews. Clinical Oncology·Christopher G KanakryLeo Luznik
Apr 2, 2002·Best Practice & Research. Clinical Haematology·P J Henslee-Downey
Mar 11, 2015·Scandinavian Journal of Immunology·L Minculescu, H Sengeløv
Dec 25, 2012·Oncoimmunology·Julie Gertner-DardenneDaniel Olive
Jun 22, 2012·Oncoimmunology·Gabrielle M Siegers
Mar 4, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Lawrence S Lamb, Richard D Lopez
Jan 8, 2015·Frontiers in Immunology·Drew C DenigerLaurence J N Cooper
Jun 5, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Gabrielle M Siegers, Lawrence S Lamb
Apr 24, 2018·Journal of Immunotherapy·Noémie JoallandEmmanuel Scotet
Jan 24, 2018·Blood·Rupert Handgretinger, Karin Schilbach
Sep 25, 2019·Clinical & Translational Immunology·Lucy C SullivanGlen P Westall
Jul 12, 2018·Transplantation·Oliver McCallionFadi Issa
May 21, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Telma LançaBruno Silva-Santos
Jul 10, 2013·The Journal of Immunology : Official Journal of the American Association of Immunologists·Thibault SantolariaEmmanuel Scotet
Jul 5, 2017·Biomedicines·Haitham AbdelhakimAyman Saad
May 5, 2018·Frontiers in Immunology·Timm HoeresMartin Wilhelm
May 8, 2020·JCI Insight·Melinda A BiernackiMarie Bleakley
Mar 9, 2019·International Journal of Molecular Sciences·Tsui Lien MaoChao Lien Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.